secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001730463-24-000059
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus reports Q1 2024 net loss of $52.7M; cash $758.5M; obe-cel PDUFA Nov 16
------------------------------------------------------------------------------

- Net loss $52.7M ($0.24 diluted EPS) vs $39.8M loss year ago; license revenue $10.1M.
- Cash $758.5M at March 31, 2024, up from $239.6M Dec 31, after $350M offering and BioNTech financing.
- Obe-cel BLA under FDA review; PDUFA target action date Nov 16, 2024; MAA accepted by EMA.
- First two patients enrolled in SLE Phase 1 (CARLYSLE); initial data expected end of 2024.
- BioNTech strategic collaboration ($50M upfront, up to $582M milestones) and $200M private placement; Mike Bonney appointed Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/0001730463-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/autl-20240517.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer